×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 3 - Safety - Tumorigenicity
Session Chair(s)
Shin Kawamata, MD, PhD
Director, R&D Center for Cell Therapy
Translational Research Center for Medical Innovation(TRI), Japan
Yasuko Terao, PhD
Head, External Scientific Engagement, R&D Japan Region,
Takeda Pharmaceutical Co., Ltd., Japan
Speaker(s)
Approaches to Tumorigenicity Assessment of Cell-Based Therapeutic Products
Yoji Sato, PhD
National Institute of Health Sciences, Japan
Head, Division of Drugs
Current Situation and Future Direction of Tumorigenicity Studies Using NGS
Tomohiro Morio, MD, PhD
Tokyo Medical and Dental University, Japan
Professor
MEASURE - Multisite Evaluation Study on Analytical Methods for Non-Clinical Safety Assessment of hUman-Derived REgenerativeMedicalProducts
Keiji Yamamoto, DVM, PhD, MBA
Takeda Pharmaceutical Company Limited, Japan
Senior Director, Japan Drug Safety Research Laboratories
Have an account?